Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13947MR)

This product GTTS-WQ13947MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13947MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11626MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ3342MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ10697MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ15019MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ1987MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ14827MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-75
GTTS-WQ6998MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ2153MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALD-518
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW